Skip to content

Iron and Vaccine Response

Iron and Vaccine-preventable Viral Disease - an Experimental Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04912661
Enrollment
121
Registered
2021-06-03
Start date
2021-05-29
Completion date
2021-09-09
Last updated
2021-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia, Iron Deficiency Anemia Treatment, Vaccine Preventable Disease, Vaccine Response Impaired

Brief summary

Vaccines often underperform in Africa compared to high-income countries. Why vaccines do not work as well in Africa remains uncertain. Malnutrition likely plays a role. Our study objective is to assess whether iron deficiency anaemia in young women impairs their immune response to viral vaccines, and whether iron treatment improves their response.

Detailed description

Group 1 (immediate iron treatment) will receive iron treatment before vaccination. Women in both groups will receive two intramuscular vaccines (influenza and yellow fever). Vaccine response will be measured 28 and 56 days after vaccine administration in both groups. Group 2 (delayed iron treatment) will receive iron treatment at study end.

Interventions

DIETARY_SUPPLEMENTFerinject

intravenous iron carboxymaltose

Sponsors

Jomo Kenyatta University of Agriculture and Technology
CollaboratorOTHER
Swiss Federal Institute of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-55 years old * Zinc protoporphyrin \> or equal 40 mmol/mol heme * hemoglobin \< or equal 109 g/L * no malaria * no known HIV infection * no medical condition that precludes study involvement * no iron supplementation 1 week prior to study start * no recent tuberculosis infection * no vaccination of yellow fever or influenza prior to enrolment * not pregnant

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Antibody titersat 35 days
Seroconversionat 35 days
Antibody avidity Indexat 35 dayspercentage of antibodies that remain bound to beads

Secondary

MeasureTime frameDescription
Transcriptomicsday 0Genes involved in immune response
Immune cell cytokine secretionday 7ELISpot
Hemoglobinday 0iron status parameter
Plasma Ferritinday 0iron status parameter
Transferrin receptorday 0iron status parameter
antiviral immunoglobulin G responseday 0Immunoassay
C-reactive proteinday 0inflammation status parameter
Alpha-glycoproteinday 0inflammation status parameter
retinol binding proteinday 0marker for Vitamin A status
plasma zincday 0
Transferrin saturationday 0iron status parameter
immune cell populationsday 0number and type of immune cells
Proteomicsday 0Proteins involved in immune response

Countries

Kenya

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026